Rat Anti-Glomerular Basement Membrane Disease (GBM) Models

Anti-glomerular basement membrane (GBM) disease is a rare autoimmune disorder caused by pathogenic antibodies targeting the noncollagenous domain of the α3 chain of type IV collagen, leading to rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage (DAH). Without rapid intervention, the disease can progress to kidney failure. HKeyBio offers a well-validated anti-GBM serum induced model in SD rats, established by direct administration of heterologous anti-GBM antibodies. This model recapitulates key human GBM disease features including acute onset, severe crescentic glomerulonephritis, elevated serum creatinine, proteinuria, increased urinary albumin-to-creatinine ratio (UACR), and characteristic histopathological changes (crescent formation, inflammatory infiltration). It provides a robust platform for preclinical efficacy testing of novel immunomodulatory therapies including plasma exchange mimetics, glucocorticoids, cyclophosphamide, and biologics such as rituximab.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Multiple susceptible strains – C57BL/6, DBA/1 mice and Wistar rats available to suit different genetic backgrounds and experimental needs.

Clinically relevant – Recapitulates human anti-GBM disease with acute crescentic glomerulonephritis, renal dysfunction, and characteristic histopathology.

Comprehensive endpoints – Body weight, serum CREA-S, proteinuria, UACR, renal histopathology (HE scoring and crescent quantification).

Mechanism-driven – Direct antibody-mediated injury to glomerular basement membrane triggers complement activation and inflammatory cascade.

Translational value – Ideal for testing immunosuppressants (cyclophosphamide, glucocorticoids), biologics (rituximab, anti-CD20), complement inhibitors, and plasma exchange mimetics.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

Anti-GBM Induced GBM Model

43c272c13f07ee019c4bad69d75d7cbf

Applications

• Efficacy testing of immunosuppressants (cyclophosphamide, glucocorticoids, mycophenolate)

• Evaluation of biologics (rituximab, anti-CD20, anti-CD19) and plasma exchange mimetics

• Testing of complement inhibitors (anti-C5, C5aR antagonists)

• Target validation for antibody-mediated glomerulonephritis

• IND-enabling pharmacology and toxicology studies

Model Specifications

Parameter	Specification
Species/Strain	Sprague-Dawley (SD) rat
Induction method	Intravenous injection of heterologous anti-GBM serum (nephrotoxic serum)
Study duration	7–21 days (acute phase)
Key endpoints	Body weight, serum creatinine (CREA-S), proteinuria, urinary albumin-to-creatinine ratio (UACR), blood urea nitrogen (BUN), renal histopathology (HE staining with crescent scoring, glomerulonephritis assessment), optional: complement deposition (C3 immunofluorescence), lung histopathology for alveolar hemorrhage
Data package	Raw data, analysis reports, clinical chemistry, urine analysis, histology slides, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What GBM preclinical model do you provide?

A1: We offer the anti-GBM serum induced model using SD rats, which is a classic animal model for studying anti-glomerular basement membrane disease.

Q2: What is the modeling mechanism?

A2: Heterologous anti-GBM antibodies are administered to induce typical crescentic glomerulonephritis. The model features acute onset, severe renal lesions and excellent reproducibility, simulating the pathological process of human anti-GBM disease.

Q3: What evaluation indicators are used for assessment?

A3: We monitor body weight clinically. Key biochemical indicators include UACR, CREA, UREA and proteinuria. HE staining is also performed to observe renal pathological changes.

Q4: What is the modeling cycle and key time points?

A4: Anti-GBM antibody is injected on Day 0. All animals are sacrificed on Day 14 to complete sample collection and relevant detections.

Q5: What are the advantages and application scenarios?

A5: This model stably reproduces the symptoms and pathological features of anti-GBM nephritis. It is widely applied for preclinical efficacy screening, mechanism research and safety evaluation of drugs for autoimmune kidney diseases.